Biocon’s Pertuzumab Becomes First Biosimilar

Biocon Ltd secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach Shreehas Tambe, CEO & Managing Director, Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe. As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA's tailored clinical development approach, it reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.” Opinion : This news will have positive impact on the stock price of Biocon in short run. Dislcaimer : I do not hold this stock. This is not a buy , sell or hold recommencation on the stock